All In Biotech

NDA 022499 · Tris Pharma INC

Clonidine

Clonidine · Oral

Discontinued

Last checked: Nov 20, 2026Latest source record: Sep 23, 2010 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Dec 3, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

276

54 Phase 3, 19 recruiting

FAERS reports

51,051

35,850 serious, 6,117 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • CLONIDINE · CLONIDINE EQ 0.09MG BASE/ML · SUSPENSION, EXTENDED RELEASE, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Clonidine" as an intervention, any sponsor and status, largest first.

All 276 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,904
  • pain3,144
  • nausea3,068
  • fatigue3,049
  • off label use3,044
  • headache2,949
  • hypertension2,701
  • dyspnoea2,375
  • diarrhoea2,359
  • vomiting2,146
  • chronic kidney disease2,116
  • dizziness1,933

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004509
2005983
2006964
2007945
2008929
20091,298
20101,558
20111,791
20121,951
20131,768
20142,447
20152,894
20163,175
20173,151
20183,590
20193,734
20203,081
20212,797
20222,531
20232,811
20242,942
20252,897
20262,305

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Clonidine (Clonidine)

2024 spending

$60.5M

Beneficiaries

105,840

473,634 claims

Per beneficiary

$572

$18.68 per unit

View as table
YearSpending
2020$76,482,221
2021$77,544,768
2022$76,073,174
2023$75,620,402
2024$60,540,565

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,240 on PubMed

Sponsor: Tris Pharma INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.